NYSE$NUVB
Nuvation Bio Inc · Q1 2024 earnings
Q1 2024 earnings · · Investor relations
Briefing
Nuvation Bio transformed into a late-stage, global oncology company and advanced multiple clinical programs.
Nuvation Bio reported its Q1 2024 financial results, highlighting the acquisition of AnHeart Therapeutics and the treatment of the first patient in a Phase 1/2 study of NUV-1511. The company's cash, cash equivalents, and marketable securities totaled $597.0 million as of March 31, 2024. The net loss for the quarter was $14.8 million, or $(0.07) per share.
- Completed the acquisition of AnHeart Therapeutics, transforming Nuvation Bio into a late-stage, global oncology company.
- Treated the first patient in a Phase 1/2 study of NUV-1511, the company’s first drug-drug conjugate (DDC).
- Cash, cash equivalents, and marketable securities of $597.0 million as of March 31, 2024.
- Updated data from the pivotal Phase 2 TRUST-I clinical study of taletrectinib will be presented at the 2024 ASCO Annual Meeting.
Headline financials
Revenue & EPS history
Nuvation Bio · Revenue · Quarterly
$0
Forward guidance
Nuvation Bio is scaling its organization to potentially become a commercial organization by the end of 2025, while continuing to advance multiple internal programs in various stages of preclinical and clinical development.
Tailwinds
- Expected timing of becoming a commercial organization.
- Potential therapeutic benefit of Nuvation Bio’s product candidates.
- Potential of the DDC platform.
- Advancement of preclinical and clinical programs.
- Strength of Nuvation Bio’s balance sheet.
Headwinds
- Challenges associated with conducting drug discovery and initiating or conducting clinical studies due to difficulties or delays in the regulatory process.
- Difficulties or delays in enrolling subjects or manufacturing or acquiring necessary products.
- Emergence or worsening of adverse events or other undesirable side effects.
- Risks associated with preliminary and interim data, which may not be representative of more mature data.
- Competitive developments.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2024
+1.1%
Avg return
Earnings day
+2.7%
Avg return
5 days after
+9.3%
Avg return
30 days after
60%
12 / 20 earnings
Positive
+16.4%
Q3 2023
Best reaction
-25.2%
Q4 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -2.0% | +6.7% | +4.9% | |
| Q4 2025 | -25.2% | -21.4% | -24.5% | |
| Q3 2025 | -6.2% | -8.5% | +60.7% | |
| Q1 2025 | +3.5% | +7.4% | +21.6% | |
| Q4 2024 | +1.0% | +0.0% | +0.5% | |
| Q3 2024 | +12.9% | +29.7% | +22.8% | |
| Q2 2024 | -11.3% | -15.8% | -10.4% | |
| Q1 2024 | -2.1% | -1.5% | -11.3% | |
| Q4 2023 | +13.2% | +10.7% | +84.8% | |
| Q3 2023 | +16.4% | +15.5% | +14.7% | |
| Q2 2023 | +0.5% | +12.0% | -10.4% | |
| Q1 2023 | +4.4% | +0.6% | +6.9% | |
| Q4 2022 | +1.2% | +0.6% | +8.4% | |
| Q3 2022 | -3.7% | -7.4% | -7.8% | |
| Q2 2022 | +7.8% | +12.1% | +26.8% | |
| Q1 2022 | -1.8% | -9.3% | -18.4% | |
| Q4 2021 | -8.3% | -13.7% | +0.8% | |
| Q3 2021 | +3.6% | +6.2% | +4.0% | |
| Q2 2021 | +8.6% | +4.3% | +11.1% | |
| Q1 2021 | +8.9% | +26.7% | -0.1% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro